N/A N=240 The Effect of Video Education on Skin-to-Skin at the Time of Delivery
Kangaroo Care · Video · Prenatal Education
Primary: Intention to Practice Skin-to-skin Contact After Birth — 100; 107; NA; 118 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=187 GER Poses a Potential Risk for Late Complications of BPD
Gastroesophageal Reflux · Bronchopulmonary Dysplasia
Primary: the Late Complications of BPD Infants — 57; 45; 30; 4 Participants
Phase 2 N=200 A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
Phase 4 N=954 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Carcinoma, Basal Cell · Carcinoma, Squamous Cell · Skin Neoplasms
Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93
Phase 2 N=1 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Ectropion · Skin Neoplasms
Primary: Graft Size Change — 10 percent change in graft
Phase 3 N=34 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
Acute Graft Versus Host Disease
Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients
N/A N=60 Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure
Heart Failure
Primary: Change in Peak Oxygen Uptake (VO2) During Maximal Effort Exercise Stress Test According to Ejection Fraction Subgroups — 1.5; -0.5; 2.0; -1.0 percentage of change in…
N/A N=193 Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza
Influenza
Primary: Duration of Influenza Illness — 4; 4 days
N/A N=47 The Effects of Menstrual Cycle Phase on Exercise Treadmill Test Results in Premenopausal Women
Menstrual Cycle · Exercise Treadmill
Primary: ST/HR Index (μV/Bpm) — 1.2; 1.3 μV/Bpm — p=0.521
N/A N=414 Augment® Bone Graft (Formerly GEM OS™1 Bone Graft) Compared to Autologous Bone Graft in Foot and Ankle Fusions
Foot Fusion
Primary: Subjects Fused at 24 Weeks (as Determined by CT Assessment) — 85; 159 Participants
N/A N=299 Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Degenerative Joint Disease · Congenital Deformity · Arthritis
Primary: Pain on Weight Bearing — 71.0; 70.7; 29.5; 28.2 units on a scale
Phase 2 N=40 TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds
Donor Site Complication
Primary: Number of Participants With Treatment-related AEs and SAEs (Including Infections and Bleeding) — 0; 0; 0; 0 Participants
Phase 2 N=30 Clinical Study on Silk Sericin Wound Dressing for Split-thickness Skin Graft Donor Sites Treatment
Late Complication From Skin Graft · Infection of Skin Donor Site · Impaired Wound Healing
Primary: Clinical Efficacy of Wound Dressing Containing Silk Sericin for Split-thickness Skin Graft Donor Site Treatment — 12 Days
Phase 2 N=61 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Hematologic Malignancies · Graft vs Host Disease
Primary: 100-day Cumulative Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) — 22 percentage of participants
Phase 2 N=40 A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease
Graft vs Host Disease
Primary: Percentage of Patients That Respond to Treatment — 65 percentage of patients